FDA Warns of Secondary Cancer Risk Tied to CAR-T Therapies That Treat Cancer

The US FDA has issued a new warning about the possible risk of secondary cancers in cancer patients who have been treated with a form of immunotherapy called chimeric antigen receptor T-cell, or CAR-T cell, therapy.